Introduction
The survival rate for children and young adults with cancer have improved substantially over the past few decades'2 largely because of advances in treatment.
In the 1970s, chemotherapeutic drugs used in combination were shown to increase complete remission rates. Thus, many children or young adults treated for cancer in the past 10-15 years will have received multiple chemotherapeutic drugs, possibly in addition to radiotherapy.' Because much of the treatment is known to be mutagenic and is designed to interfere with the DNA and normal cellular function, there may be adverse effects on reproduction.
Although some animal studies support the relation between radiation and chemical exposure and abnormalities in the offspring,46 evidence in humans is inconclusive. The higher rates of adverse reproductive outcomes, including congenital anomalies, found among mothers treated with radiotherapy before conception are thought to be primarily due to radiation induced uterine damage rather than to germ cell mutations.7-9 Although most studies have not found an association between cancer therapy and congenital anomalies in the offspring,'''" the power to detect moderate increases in risks has generally been limited and few have looked specifically at conditions that might be expected to result from a therapy induced germ cell mutation.
We conducted a case-control study to determine the association between congenital anomalies in the children of those who had cancer diagnosed or treated before conception. We also examined the risks associated with specific cancer therapies and the risks of specific anomalies that could be produced by a new mutation.
Subjects and methods
The figure summarises the methods used in the study. Cases were defined as the parents of children who were recorded in the database of the Canadian Information on the parents of these children was retrieved from birth certificates by computerised linkage with the Ontario birth file. By using the generalised iterative record linkage system,'3 followed by abstraction from paper files we found a birth certificate for 97% of the records in the anomaly database.
For each set of case parents, one set of control parents was randomly selected from the Ontario birth file. Parents were matched for year of birth of the child, birth order of the child ( dose were noted. We also noted name, starting and stopping dates, and dose for each chemotherapeutic drug. Data were also collected on pelvic surgery. The alkylating agents (cyclophosphamide, melphalan, and mustine) were analysed together because they are thought to have the greatest mutagenic potential; procarbazine was included with these because of its similar mode of action.'5 An alkylator score was calculated to summarise subjects' exposure. For each alkylating agent received a score of one or two was assigned, depending on whether the dose was in the lower or upper 50% of the total distribution of doses (a score of 0 was given to those who did not receive that drug). These scores were summed across drugs and subjects with scores in the top 50% were considered to be in the high dose group. This scoring system assumes that each alkylating agent has the same mutagenic potential and that effects are additive.
Subjects who had received cobalt-60 radiotherapy to the pelvis or abdomen (most subjects who received radiotherapy had been treated with cobalt-60) were also divided into groups. The high dose group comprised subjects whose total dose of cobalt-60 was above the median dose for all subjects treated with radiation.
The results were also examined according to type of congenital abnormality. Congenital anomalies were divided on the basis of ICD code groupings. A child with anomalies in more than one subgroup could, therefore, contribute to several different subgroups. Subgroups were also created according to aetiology16: single gene disorders (autosomal dominant disorders, autosomal recessive disorders, and X linked disorders); chromosomal disorders (autosomal and X chromosomal disorders); multifactorial disorders; suspected genetic disorders with an unknown aetiology; and anomalies with unknown aetiology. A hierarchical approach was taken so that a child with more than one anomaly contributed to only one subgroup (the order of the hierarchy was as listed above). Classification into aetiological groups was done by DJT based on the fourdigit ICD codes without knowing whether the affected child was the offspring of a cancer patient. Because the single gene disorders are thought to comprise anomalies which might be expressed in the offspring as a result of a new mutation,'6 this grouping of anomalies may be more sensitive in detecting an effect of an environmental mutagen.
The mothers and fathers were analysed separately because of the possibility of different effects of cancer therapy on the germ cells. Descriptive analyses were done by using the computer program SAS."' Relative risks were approximated by odds ratios which, along with their confidence intervals, were calculated with the EGRET statististical software package. ' BMJ VOLUME 307
The mean age at diagnosis of cancer was similar among the cases (23-1 years) and controls (23-6 years). The relative risk of anomalies in the offspring decreased with increasing age at diagnosis of cancer, although none was significantly different from unity (relative risk= 1-4, 1 0, and 0 7 for mothers under 20, 20 to 29, and over 29 years at the time of diagnosis). Table I shows the relative risks and 95% confidence intervals associated with cancer treatment. The risk for each category reflects any treatment within that category, regardless of other types of treatment which may have been given. No significant change in risk was seen for any category of treatment. We could not look at the dose effect because of the small number of mothers treated with radiotherapy or chemotherapy. No significant increase in risk was seen in the four ICD anomaly subgroups with the most cases (table II) .
Results for each subgroup were based on all casecontrol pairs for which the case's child had an anomaly within that subgroup. The relative risks of treatment with either radiotherapy or chemotherapy associated with anomalies of the heart and circulatory system and anomalies of the genital organs were 2-0 (0 4 to 18-0) and 4 0 (0 3 to 7-0) respectively. Table II also shows the results of the analyses according to aetiological groupings of anomalies. The number of subjects in the group with single gene disorders was small and therefore, although the risk was increased, the confidence interval was wide. None of the subjects in this subgroup who had had cancer were treated with an alkylating agent or radiotherapy to the pelvis or abdomen.
FATHERS
Among the fathers, 61 cases and 65 controls were found to have had cancer (relative risk=0 9, 95% confidence interval 0 7 to 1-4). The most common cancers were Hodgkin's disease, testicular cancer, melanoma, and brain cancer. About half of the cases (32) and 29 of the controls had not received chemotherapy or radiotherapy for their cancers. The mean ages at diagnosis were 28-0 years for the cases and 25-4 years for the controls. The risk of a congenital anomaly among the offspring did not decrease with increasing age at diagnosis (relative risk=0-5, 1-0, and 1-2 for fathers under 20, 20-29 years, and over 29 years at the time of diagnosis). Not enough subjects were diagnosed and treated before the age of puberty (when the germ cells are inactive) to evaluate risk in this subgroup.
The risk associated with the various forms of cancer therapy and anomalies in the offspring did not differ significantly from unity (table III) . There was no evidence that the risk of congenital anomalies among the offspring rises with increasing dose of alkylating agents, although the confidence intervals were wide (relative risk 1-2, 95% confidence interval 0 3 to 4-2 for those in the lower dose group and 1 0, 0-2 to 5-4 for those in the higher dose group birth record corresponding to each anomaly record) are unlikely since links were verified with information available on the paper copy of the birth certificate. Likewise, because a birth certificate was found for 97% of the children in the anomaly database, the false negative rate should be low. A likely reason why birth certificates were not found for the remaining 3% is that the birth occurred outside Ontario but the child was admitted to hospital in Ontario during the first year of life. Since this group was not eligible for the study, these omissions would not result in bias.
It is more difficult to estimate the number of parents missed in the linkage between the case-control file and the Ontario cancer registry. The number of links among fathers agreed closely with that expected under the null hypothesis. However, slightly fewer mothers than expected were linked to the registry. Some true links for mothers may have been missed because of name changes between diagnosis of cancer and the birth of the child, resulting in them being wrongly classified as not having had cancer. Because identifying information on cases and controls was comparable and the linkage to the cancer registry was done without knowledge of case-control status any misclassification should have affected cases and controls equally. Although misclassification would drive the relative risk towards unity, it is unlikely that misclassification accounted for the lack of effect observed in this study. False positive links to the cancer registry are improbable because nearly all accepted links were confirmed through data found in medical records.
Parents who had cancer diagnosed while resident outside Ontario wouid not appear in the Ontario cancer registry and therefore would have been incorrectly classified, as not having had cancer. Cases and controls were matched for birth place to minimise the possibility of any such misclassification biasing the results. Among both mothers and fathers, the risks associated with previous cancer and anomalies in their offspring are similar in the subroups of parents bom in and outside of Ontario. Thus the relative risks for those bom outside of Ontario seem unlikely to be biased because of case-control differences in the likelihood of linking to the cancer registry.
EFFECT OF CANCER TREATMENT
The treatments most likely to be mutagenic ( control mothers in this subgroup were treated with these therapies. These findings are somewhat difficult to interpret because of the small numbers of subjects in this anomaly subgroup. In addition, the grouping of anomalies by aetiology was based on the limited information in the anomaly database, namely the four digit ICD-9 codes for anomalies recorded through the first year of life. Since family histories were not known, some of the anomalies observed in the offspring may have been familial rather than the result of a new mutation. Although the anomalies were assigned to groups by one person who was blinded to parental exposure, the lack of detailed diagnostic and familial information may have resulted in some misclassification of both cases and controls. Given the rarity of single gene disorders and the likelihood that any increase in risk will not be large, many subjects will be needed to conclusively determine the risks associated with cancer therapy and these disorders.
Studies that have examined ICD subgroups of anomalies have not shown consistent associations with any particular subgroup. However, Green et aT' recently reported a possible association between women treated with dactinomycin and cardiac defects among their offspring. We found that relative risks for the subgroup of cardiac anomalies were moderately but not significantly increased in both the mothers and the fathers, although no association was found with dactinomycin.
CONFOUNDING
Studies that use data collected for other purposes are limited by the information available in the databases. In this study, confounder information comprised that available from birth certificates. We were therefore able to match (and control for) some potential indicators of socioeconomic status (parental age, marital status), although residual confounding with socioeconomic status may exist. Other potential confounders were not available on the birth certificate for example, smoking, alcohol. Since most of the cases of cancer were diagnosed by early adulthood, it is not unlikely that these factors would be strongly related to the development of cancer. It seems reasonable to assume that few, if any, other factors would be strongly related to both congenital anonmalies in the offspring and cancer in a parent. The known advantages of using existing data that is, the ability to study large numbers of subjects at a relatively low cost-outweighed the possibility of a small amount of bias associated with the lack of information on potential confounding variables.
A recent study of occupational exposure to ionising radiation among fathers and leukaemia in their children suggested that the observed increased risk was due to a cell mutation which was leukaemogenic in the offspring. 23 The results also suggested that exposure during the six months before conception may be the most relevant. We found no evidence of increased risk among fathers treated with either radiotherapy or an alkylating agent within a year of conception, although the numbers were small. As many cancer patients are advised to wait a year after treatment before conceiving it may be difficult to analyse the risk of anomalies in the offspring among parents who are treated within a year of conception. 24 Our results should offer some reassurance to people who survive cancer. They suggest that, among live-BMJ VOLUME 307 Clinical implications * Young adults and children now commonly survive treatment for cancer and subsequently want to have a family * Many fear that the toxic treatment they received for cancer will affect their children * This study shows that the risk of having a child with congenital anomalies was not increased among parents who had been treated for cancer * For live births there was no relation between increasing toxicity of treatment and congenital anomalies * Cancer patients can be reassured that any livebom offspring are unlikely to be affected by cancer treatment bom offspring, the probability of having a child with a congenital anomaly is not appreciably different for those who have had cancer or been treated for cancer from that for the general population.
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